These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21794800)

  • 1. [Predictors of response to biologic therapies in rheumatoid arthritis].
    Chaves Chaparro LM; Salvatierra Ossorio J; Raya Álvarez E
    Reumatol Clin; 2011; 7(2):141-4. PubMed ID: 21794800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis.
    Szodoray P; Szabó Z; Kapitány A; Gyetvai A; Lakos G; Szántó S; Szücs G; Szekanecz Z
    Autoimmun Rev; 2010 Jan; 9(3):140-3. PubMed ID: 19427413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach.
    Matsuo K; Xiang Y; Nakamura H; Masuko K; Yudoh K; Noyori K; Nishioka K; Saito T; Kato T
    Arthritis Res Ther; 2006; 8(6):R175. PubMed ID: 17125526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker.
    Nijenhuis S; Zendman AJ; Vossenaar ER; Pruijn GJ; vanVenrooij WJ
    Clin Chim Acta; 2004 Dec; 350(1-2):17-34. PubMed ID: 15530456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.
    Boire G; Cossette P; de Brum-Fernandes AJ; Liang P; Niyonsenga T; Zhou ZJ; Carrier N; Daniel C; Ménard HA
    Arthritis Res Ther; 2005; 7(3):R592-603. PubMed ID: 15899046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles.
    Snir O; Widhe M; von Spee C; Lindberg J; Padyukov L; Lundberg K; Engström A; Venables PJ; Lundeberg J; Holmdahl R; Klareskog L; Malmström V
    Ann Rheum Dis; 2009 May; 68(5):736-43. PubMed ID: 18635594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis.
    El-Gabalawy HS; Wilkins JA
    Arthritis Res Ther; 2004; 6(2):86-9. PubMed ID: 15059270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early diagnosis of rheumatoid arthritis with a test based upon a specific antigen: cyclic citrullinated peptide].
    van Venrooij WJ; van de Putte LB
    Ned Tijdschr Geneeskd; 2003 Feb; 147(5):191-4. PubMed ID: 12645351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis.
    Wegner N; Lundberg K; Kinloch A; Fisher B; Malmström V; Feldmann M; Venables PJ
    Immunol Rev; 2010 Jan; 233(1):34-54. PubMed ID: 20192991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor.
    Vander Cruyssen B; Peene I; Cantaert T; Hoffman IE; De Rycke L; Veys EM; De Keyser F
    Autoimmun Rev; 2005 Sep; 4(7):468-74. PubMed ID: 16137613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
    Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
    Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis.
    Turesson C; Bergström U; Jacobsson LT; Truedsson L; Berglund G; Saxne T
    Ann Rheum Dis; 2011 Mar; 70(3):520-2. PubMed ID: 21081527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity.
    Uysal H; Nandakumar KS; Kessel C; Haag S; Carlsen S; Burkhardt H; Holmdahl R
    Immunol Rev; 2010 Jan; 233(1):9-33. PubMed ID: 20192990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis?
    Girelli F; Foschi FG; Bedeschi E; Calderoni V; Stefanini GF; Martinelli MG
    Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):127-30. PubMed ID: 15180353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Autoantibodies as predictors of biological therapy for early rheumatoid arthritis].
    da Mota LM; dos Santos Neto LL; Pereira IA; Burlingame R; Ménard HA; Laurindo IM
    Acta Reumatol Port; 2010; 35(2):156-66. PubMed ID: 20711091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Citrullinated peptide and its relevance to rheumatoid arthritis: an update.
    Luban S; Li ZG
    Int J Rheum Dis; 2010 Oct; 13(4):284-7. PubMed ID: 21199462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.
    Bang H; Egerer K; Gauliard A; Lüthke K; Rudolph PE; Fredenhagen G; Berg W; Feist E; Burmester GR
    Arthritis Rheum; 2007 Aug; 56(8):2503-11. PubMed ID: 17665451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.